Subha Vogeti, Ph.D.

Subha Vogeti, Ph.D., is a Cell and Molecular biologist with very good experience in oncology preclinical drug discovery and an expertise to establish robust screening assays and flow schemes to support various discovery programs. With over 10 years in the biotech industry, most of it at Deciphera Pharmaceuticals, she was a significant contributing member in multi-disciplinary kinase inhibitor programs which resulted in marketed drug Qinlock and other clinical candidates DCC-3014 (Vimseltinib), DCC-2036 (Rebastinib), LY3009120 and DCC-3116 (ULK program).

She has also worked as Scientist at Agilux Laboratories in Pharmacology and Oncology division. Most recently at Deciphera Pharmaceuticals, she has co-led a discovery program from target identification to delivery of development compound to Deciphera Clinical Compound (DCC) status to support IND enabling studies. Her most favorite is RAF discovery program because of the very complex, exciting biology and to the large unmet need in cancers driven by RAS-RAF pathways.

Subha has a Ph.D. in Plant Pathology from Osmania University, India and has post doctoral training from University of Kansas, KU and VA medical Centre, Kansas City Missouri. Before joining New Equilibrium, as Director of Biology, she worked as a Principal Investigator/ Director at Deciphera Pharmaceuticals and has several publications from different programs at Deciphera.